IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3190
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$10M
Luis Merchan
Flora Growth Corp., a cannabis company, cultivates, processes, and supplies cannabis products to pharmacies, medical clinics, and cosmetic companies. The company's brand includes Mambe, Mind Naturals, Almost Virgin, Flora Lab, and Stardog Loungewear. It also manufactures and sells hemp textiles products focuses on servicing the hospitality, medical, and clothing industries.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$FLGC Flora Growth Corp. | 43 | 35 | 22 | 52 | - | - | -49.2% | -72.6% | 3.4% | -33.5% | -68.3% | 34.7% | 0.0% | 4.0x | $10M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Flora Growth Corp. (FLGC) receives a "Reduce" rating with a composite score of 42.5/100. It ranks #3190 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Luis Merchan
Chief Executive Officer
Labor Force
280
35
19
3
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for FLGC
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for FLGC.
View All RatingsImproving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
ROE proxy -49.2% (sector -2.5%)
GM 3% vs sector 43%, OM -34% vs sector 1%
Capital turnover N/A
Rev growth 35%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Flora Growth Corp. receives a Reduce rating from our analysis, with a composite score of 42.5/100 and 2 out of 5 stars, ranking #3190 out of 7,333 stocks. FLGC's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
FLGC's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -49.2% (sector avg: -2.5%), gross margins of 3.4% (sector avg: 42.5%), net margins of -68.3% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
FLGC registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.15x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Flora Growth Corp.'s investment score of 19/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 34.7% vs. a sector average of 5.9% and a return on assets of -72.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
FLGC demonstrates moderate momentum with a score of 52/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 34.7% year-over-year. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
Flora Growth Corp. registers a low stability score of 3/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a debt-to-equity ratio of 4.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
FLGC's short interest factor score of 87/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 4.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $10M, Flora Growth Corp. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Flora Growth Corp. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3190 of 7,333 overall (56th percentile). Key comparisons include ROE of -49.2% trailing the -2.5% sector median and operating margins of -33.5% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While FLGC currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (3) would have the largest impact on the composite score.
ROE 1883% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 92% BELOW SECTOR MEDIAN
Op. Margin 2697% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Flora Growth Corp. (FLGC) as a Reduce with a composite score of 42.5/100 at a current price of $8.88. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (52th percentile) and quality (35th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (3th percentile) and investment (19th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), High uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Flora Growth Corp. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 42.5/100 places it at rank #3190 in our full 7,333-stock universe. At $10M in market capitalization, Flora Growth Corp. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 35%, though momentum at the 52th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 3% (-39.1pp vs sector) narrow to operating margins of -34% (-34.8pp vs sector) and net margins of -68.3%, yielding a gross-to-net conversion rate of -1986%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $8.88, Flora Growth Corp. is trading at a premium to fundamental value. Our value factor score of 22/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.1x, P/S of 0.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Revenue growth of 35% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (4% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Reduce rating (composite 42.5/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -68.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Elevated short interest (87th percentile) indicates that sophisticated market participants are betting against the stock.
We assign a High uncertainty rating to Flora Growth Corp.. Key risk factors include current negative profitability (net margin -68.3%), below-average price stability (3th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -68.3%); below-average price stability (3th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 3th percentile and quality factor at the 35th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (4% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Flora Growth Corp.'s capital allocation as Poor. Key concerns include low returns on equity (-49.2%), negative profitability, weak asset returns (ROA -72.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Flora Growth Corp. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Flora Growth Corp. receives a Reduce rating with a composite score of 42.5/100 (rank #3190 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 26/100.
Our analysis does not support a constructive view on Flora Growth Corp. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Flora Growth Corp. a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 15.8/20.
The strongest moat sources are growth durability (15.8/20) and financial resilience (9.4/20). Rev growth 35%, 5yr history. Interest coverage N/A. These pillars form the core of Flora Growth Corp.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and margin superiority (0.4/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Flora Growth Corp.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include robust top-line growth of 35% expanding the revenue base. The margin cascade from 3% gross to -34% operating to -68.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 35th percentile.
The margin profile shows gross margins of 3%, operating margins of -34%, net margins of -68.3%. Return metrics include ROE of -49.2% and ROA of -72.6%. Relative to the Manufacturing sector, gross margins are 39.1 percentage points below the sector median of 43%, and ROE of -49.2% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 4%, revenue growth of 35%. The sector median D/E is 0%, putting Flora Growth Corp. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Flora Growth Corp. (NASDAQ: FLGC) (the "Company"), today announced it has commenced an underwritten public offering of its common shares. All common shares in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.R.F. Lafferty & Co., Inc. is acting as the sole...

Shares of Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter. The company reported quarterly losses of 81 cents per share, according to data from Benzinga Pro. Alcoa still sees full-year alumina production of between 9.8 million and 10 million metric tons and full-year alumina shipments between 12.7 million and 12.9 million metric tons. Alcoa shares jumped 3% to $36.60 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Tian Ruixiang Holdings Ltd (NASDAQ: TIRX) shares gained 155.6% to $1.24 in pre-market trading after gaining around 8% on Wednesday. MicroCloud Hologram Inc. (NASDAQ: HOLO) gained 51.8% to $3.40 in pre-market trading after falling around 5% on Wednesday. Smart for Life, Inc. (NASDAQ: SMFL) shares gained 28.4% to $0.6035 in pre-market trading after gaining over 21% on Wednesday. Tantech Holdings ...

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations. Esperion Therapeutics shares climbed 7.1% to $3.47 pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Longeveron Inc. (NASDAQ: LGVN) rose 93.2% to $4.25 in pre-market trading after gaining 8% on Friday. Antelope Enterprise Holdings Limited (NASDAQ: AEHL) shares rose 47% to $2.20 in pre-market trading after declining 5% on Friday. On April 1, Antelope Enterprise announced preliminary full year 2023 revenue of $70.4 million. DigiAsia Corp. (NASDAQ: FAAS) shares rose 31.6% to $8.46 in pre-market trading after the jumping around 17% on Friday. BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) gained 27.2% to $1.31 in pre-market trading. Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 25.6% to $0.2840 in pre-market trading after dipping over 8% on ...

Shares of Reliance Global Group, Inc. (NASDAQ: RELI) fell sharply in today’s pre-market trading after reporting financial results for the year ended Dec 31, 2023. Reliance Global Group posted a net loss of $12.0 million for 2023, compared to net income of $6.5 million in 2022.. Reliance Global Group shares tumbled 11.3% to $0.47 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers MediaCo Holding Inc. (NASDAQ: MDIA) rose 175% to $3.85 in pre-market trading. Mediaco 13D/amended filing showed Standard General L.P. reported a 95.2% stake in the company, as of April 1, 2024. Nutex Health Inc. (NASDAQ: NUTX) shares rose 50.4% to $0.1349 in pre-market trading after gaining 3% on Thursday. 22nd Century Group, Inc. (NASDAQ: XXII) gained 50% to $2.22 in pre-market trading after dipping 16% on Thursday. On March 28, 22nd Century reported fourth-quarter earnings and announced a stock split of 1-for-16. Next.e.GO N.V. (NASDAQ: EGOX) gained 29.7% ...

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares climbed 130.1% to $2.9790. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Allurion Technologies Inc. (NASDAQ: ALUR) gained 70% to $2.8801 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a Buy rating and announced a $5 price target. Tevogen Bio Holdings Inc. (NASDAQ: TVGN) shares climbed 40.6% to $3.58. Tevogen Bio, on Wednesday, appointed Tapan V Shah as Head of Investor Relations and Corporate Development. HWH International Inc. (NASDAQ: HWH) gained 38.8% to $2.1765. Candel Therapeutics, Inc. (NASDAQ: CADL) rose 36.3% to $2.2899 after the company announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer. MacroGenics, Inc. (NASDAQ: MGNX) climbed 27.8% to $17.47. MacroGenics announced TAMARACK study data will not be presented at the ASCO Annual Meeting. E-Home Household Service Holdings Limited (NASDAQ: EJH) gained 27% to $2.22. Reliance Global Group, Inc. (NASDAQ: RELI) gained 24.6% to $0.46 after the company reported FY23 earnings. Simulations Plus, Inc. (NASDAQ: SLP) rose 22.5% to $47.12 after the company posted better-than-expected results for its second quarter. Vast Renewables Limited (NASDAQ: VSTE) gained 22.3% to $8.81. Sportsman's Warehouse Holdings, Inc. (NASDAQ: SPWH) gained 21.3% to $3.7950 following a narrower-than-expected quarterly loss. Gorilla Technology Group Inc. (NASDAQ: GRRR) jumped 19% to $0.8729 after the company reported a year-over-year increase in FY23 sales results. Levi Strauss & Co. (NYSE: LEVI) shares rose 18.3% to $22.10 after the company reported upbeat earnings ...